Beta-carbonic anhydrase 1 (MtCA1) (MtCA1)

Beta-carbonic anhydrase 1 (MtCA1), encoded by the Rv1284 gene, is an essential zinc-containing metalloenzyme in Mycobacterium tuberculosis that catalyzes the reversible hydration of carbon dioxide to bicarbonate and protons [3, 9]. This enzymatic activity is fundamental to the pathogen's survival and virulence, as it maintains intracellular pH homeostasis and provides bicarbonate required for critical metabolic processes, including fatty acid synthesis and gluconeogenesis [3, 13]. MtCA1 is highly expressed during both the active replication and the slow-growth or latent phases of infection, particularly within the stressful environment of host macrophages [5, 13]. As a therapeutic target, it is highly susceptible to inhibition by several classes of chemical compounds, including sulfonamides, sulfamates, and dithiocarbamates, which bind directly to the active-site zinc ion [2, 4]. While established drugs such as acetazolamide and ethoxzolamide demonstrate potent in vitro inhibition, current research focus is on identifying selective inhibitors that target the bacterial enzyme over human isoforms to avoid systemic side effects [10, 15]. Furthermore, overcoming the permeability barrier posed by the mycobacterial mycolic acid cell wall remains a significant challenge for translating these inhibitors into clinical treatments [4, 7].

Other names

Rv1284Carbonic anhydrase 1canAmtCA 1Beta-CA1

The compounds act as competitive inhibitors by coordinating with the catalytic zinc(II) ion in the enzyme's active site, thereby preventing the reversible hydration of carbon dioxide to bicarbonate and disrupting pH regulation and essential metabolic pathways [2, 3].